Lexaria Bioscience LEXX 深 沪
已收盘 08-28 16:00:00 美东时间
10.35
-1.330
-11.39%
华盛通- 最 高12.475
- 今 开11.42
- 成交量 6.19万股
- 最 低 10.35
- 昨 收 11.68
- 总市值 1710.33万
- 52周最高 23.25
- 市盈率 静 --
- 换手率 3.75%
- 52周最低 4.21
- 委 比 66.67%
- 总股本 165.25万
- 历史最高 187.50
- 量 比 0.57
- 振 幅 18.19%
- 历史最低 5.25
- 每 手 1
- 风险率 3.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lexaria Bioscience Completes Blood Plasma Pharmacokinetic Bioanalysis Testing In Its 2026 Animal Study 2 Evaluating Oral Delivery Of 2 Next-Generation GLP-Drugs, Amycretin And Retatrutide, In A Total Of 18 Different Study Arms In Dogs Following Use Of Its DehydraTECH Drug Delivery Platform
Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry study Proprietary DehydraTECH 3.0 retatrutide tablet formulation increased drug absorption by as much as an astonishing 4,552% compared to the DehydraTECH 2.0 retatrutid...
08-24 21:14
Lexaria Bioscience Stock Rallies Thursday: What Investors Need to Know
Lexaria Bioscience Corp. (NASDAQ:LEXX) shares are surging Thursday afternoon after announcing a new Material Transfer Agreement with Hong Kong-listed PegBio Ltd. Here’s what investors need to know. Lexaria Bioscience shares are climbing with conviction. What’s driving LEXX stock higher? Expanding De...
08-14 03:18
Lexaria Bioscience Enters Material Transfer Agreement With Pegbio To Investigate LEXX's DehydraTECH Technology With A Proprietary Pegbio Molecule Under Development For The GLP-1 Industry
Today's announcement is separate from, and has no relationship with, Lexaria's pre-existing Material Transfer Agreement with another pharmaceutical company. The MTA details the conditions under which PegBio will supply Lexaria with a proprietary GLP-1 molecule which will then be processed with Lexar...
08-13 21:05
Lexaria Bioscience Q3 EPS $(0.08) Beats $(0.09) Estimate
Lexaria Bioscience (NASDAQ:LEXX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 0 percent. This is a 61.9 percent increase over losses of $(0.21) per share from the same period last year.
07-14 06:00
Lexaria Bioscience Announces It Began Dosing On June 14 In Its Human Study GLP-1-H26-7 Evaluating Two Oral DehydraTECH-Semaglutide Compositions Against Wegovy
Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that dosing began on schedule on June 14th with Human Pilot Study #7 (GLP-1-H26-7) that is evaluating two oral DehydraTECH-semaglutide ("DHT-sema") compositions against Novo ...
06-25 21:14
Lexaria Bioscience Receives Ethics Approval For Human GLP-1 Study Comparing Oral DehydraTECH-Semaglutide Formulations To Wegovy, With Dosing Expected To Begin In Mid-June
Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that ethics approval has been received from an independent review board, for
05-19 21:17
Lexaria Bioscience Advances Human Study Of DehydraTECH-Semaglutide Versus Wegovy Tablets
Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, provides this update on Human Pilot Study #7 (GLP-1-H26-7) that will evaluate two oral
05-05 21:22
Lexaria Bioscience Engages The Contract Research Organization To Execute And Report On Its 2026 Animal Study #2 That Will Evaluate A Number Of Formulation Enhancements With Two Next-Generation GLP-1 Drugs In Animals
Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce the engagement of the contract research organization ("CRO") to execute and
04-23 21:09
Lexaria Engages CRO To Execute, Report On 2026 Animal Study GLP-1-A26-1 Evaluating Formulation Enhancements Using Both DHT-Sema GLP-1 And DHT-CBD Compositions To Explore Potential For Additional Improved Performance And Stake New IP Claims
Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce the engagement of the contract research organization ("CRO") to execute and
04-15 21:19
Lexaria Bioscience Q2 EPS $(0.06) Beats $(0.11) Estimate, Sales $20.000K Miss $100.000K Estimate
Lexaria Bioscience (NASDAQ:LEXX) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.11) by 45.45 percent. This is a 60 percent increase over losses of $(0.15) per share from
04-14 05:20
